Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease

Elizabeth Yeu,1 Damien F Goldberg,2 Francis S Mah,3 Kenneth A Beckman,4,5 Jodi I Luchs,6,7 Jonathan D Solomon,8 Darrell E White,9 Preeya K Gupta101Eastern Virginia Medical School, Virginia Eye Consultants, Norfolk, VA, USA; 2Wolstan & Goldberg Eye Associates, Torrance, CA, USA; 3Scripps Clin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yeu E, Goldberg DF, Mah FS, Beckman KA, Luchs JI, Solomon JD, White DE, Gupta PK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	dry eye amniotic membrane amnion extract cytokine inflammation. Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/a333de8516834ac48e82963aa8ad8872
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a333de8516834ac48e82963aa8ad8872
record_format	dspace
spelling	oai:doaj.org-article:a333de8516834ac48e82963aa8ad88722021-12-02T01:41:47ZSafety and efficacy of amniotic cytokine extract in the treatment of dry eye disease1177-5483https://doaj.org/article/a333de8516834ac48e82963aa8ad88722019-05-01T00:00:00Zhttps://www.dovepress.com/safety-and-efficacy-of-amniotic-cytokine-extract-in-the-treatment-of-d-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Elizabeth Yeu,1 Damien F Goldberg,2 Francis S Mah,3 Kenneth A Beckman,4,5 Jodi I Luchs,6,7 Jonathan D Solomon,8 Darrell E White,9 Preeya K Gupta101Eastern Virginia Medical School, Virginia Eye Consultants, Norfolk, VA, USA; 2Wolstan & Goldberg Eye Associates, Torrance, CA, USA; 3Scripps Clinic Torrey Pines, La Jolla, CA, USA; 4Ohio State University, Columbus, OH, USA; 5Comprehensive Eye Care of Central Ohio, Westerville, OH, USA; 6Hofstra Northwell School of Medicine, Hempstead, NY, USA; 7South Shore Eye Care, Wantagh, NY, USA; 8Bowie Vision Institute, Bowie, MD, USA; 9Skyvision Centers, Westlake, OH, USA; 10Duke University Eye Center, Durham, NC, USAPurpose: Evaluate the safety and efficacy of cryopreserved amniotic cytokine extract (ACE) in the treatment of subjects with dry eye disease (DED).Patients and methods: This was a retrospective, multicenter, chart review of adult patients with DED that instilled cryopreserved ACE drops twice-daily for 4 or 12 weeks. Patients had corneal fluorescein staining (0–20 range) and/or a lissamine green conjunctival staining score (0–18 range) of ≥3 and ≤9 in at least 1 eye and a score ≥40 (0–100 range) of eye dryness/irritation on a visual analog scale (VAS). Following completion of a treatment course, medical records were reviewed from the initiation of therapy (baseline), and at post-treatment visits (4 weeks, 8 weeks, and 12 weeks). Patient records for visual acuity, adverse events, corneal fluorescein staining, conjunctival lissamine green staining, and symptom scores of ocular dryness/irritation were reviewed for each visit, as available. Safety and tolerability were assessed through the evaluation of patient-reported adverse events recorded in the medical records.Results: A total of 54 eligible patients were identified at 7 clinical sites; 16 patients administered ACE drops for 4-weeks, and 38 patients instilled ACE drops for 12 weeks. Significant improvements in the mean changes from baseline were observed for corneal fluorescein staining, lissamine green staining, visual acuity (LogMar) and VAS ocular symptom scores at the 4-week post-treatment visit (p<0.01). Additional improvements continued out to the 12-week follow-up assessment visits. Two patients discontinued therapy due to reports of ocular burning or foreign body sensation.Conclusion: The cryopreserved ACE formulation was well-tolerated and effective in reducing the clinical signs and symptoms of DED. Conduct of a vehicle-controlled prospective study is warranted.Keywords: dry eye, amniotic membrane, amnion extract, cytokine, inflammation  Yeu EGoldberg DFMah FSBeckman KALuchs JISolomon JDWhite DEGupta PKDove Medical Pressarticledry eyeamniotic membraneamnion extractcytokineinflammation.OphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 887-894 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	dry eye amniotic membrane amnion extract cytokine inflammation. Ophthalmology RE1-994
spellingShingle	dry eye amniotic membrane amnion extract cytokine inflammation. Ophthalmology RE1-994 Yeu E Goldberg DF Mah FS Beckman KA Luchs JI Solomon JD White DE Gupta PK Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease
description	Elizabeth Yeu,1 Damien F Goldberg,2 Francis S Mah,3 Kenneth A Beckman,4,5 Jodi I Luchs,6,7 Jonathan D Solomon,8 Darrell E White,9 Preeya K Gupta101Eastern Virginia Medical School, Virginia Eye Consultants, Norfolk, VA, USA; 2Wolstan & Goldberg Eye Associates, Torrance, CA, USA; 3Scripps Clinic Torrey Pines, La Jolla, CA, USA; 4Ohio State University, Columbus, OH, USA; 5Comprehensive Eye Care of Central Ohio, Westerville, OH, USA; 6Hofstra Northwell School of Medicine, Hempstead, NY, USA; 7South Shore Eye Care, Wantagh, NY, USA; 8Bowie Vision Institute, Bowie, MD, USA; 9Skyvision Centers, Westlake, OH, USA; 10Duke University Eye Center, Durham, NC, USAPurpose: Evaluate the safety and efficacy of cryopreserved amniotic cytokine extract (ACE) in the treatment of subjects with dry eye disease (DED).Patients and methods: This was a retrospective, multicenter, chart review of adult patients with DED that instilled cryopreserved ACE drops twice-daily for 4 or 12 weeks. Patients had corneal fluorescein staining (0–20 range) and/or a lissamine green conjunctival staining score (0–18 range) of ≥3 and ≤9 in at least 1 eye and a score ≥40 (0–100 range) of eye dryness/irritation on a visual analog scale (VAS). Following completion of a treatment course, medical records were reviewed from the initiation of therapy (baseline), and at post-treatment visits (4 weeks, 8 weeks, and 12 weeks). Patient records for visual acuity, adverse events, corneal fluorescein staining, conjunctival lissamine green staining, and symptom scores of ocular dryness/irritation were reviewed for each visit, as available. Safety and tolerability were assessed through the evaluation of patient-reported adverse events recorded in the medical records.Results: A total of 54 eligible patients were identified at 7 clinical sites; 16 patients administered ACE drops for 4-weeks, and 38 patients instilled ACE drops for 12 weeks. Significant improvements in the mean changes from baseline were observed for corneal fluorescein staining, lissamine green staining, visual acuity (LogMar) and VAS ocular symptom scores at the 4-week post-treatment visit (p<0.01). Additional improvements continued out to the 12-week follow-up assessment visits. Two patients discontinued therapy due to reports of ocular burning or foreign body sensation.Conclusion: The cryopreserved ACE formulation was well-tolerated and effective in reducing the clinical signs and symptoms of DED. Conduct of a vehicle-controlled prospective study is warranted.Keywords: dry eye, amniotic membrane, amnion extract, cytokine, inflammation
format	article
author	Yeu E Goldberg DF Mah FS Beckman KA Luchs JI Solomon JD White DE Gupta PK
author_facet	Yeu E Goldberg DF Mah FS Beckman KA Luchs JI Solomon JD White DE Gupta PK
author_sort	Yeu E
title	Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease
title_short	Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease
title_full	Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease
title_fullStr	Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease
title_full_unstemmed	Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease
title_sort	safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/a333de8516834ac48e82963aa8ad8872
work_keys_str_mv	AT yeue safetyandefficacyofamnioticcytokineextractinthetreatmentofdryeyedisease AT goldbergdf safetyandefficacyofamnioticcytokineextractinthetreatmentofdryeyedisease AT mahfs safetyandefficacyofamnioticcytokineextractinthetreatmentofdryeyedisease AT beckmanka safetyandefficacyofamnioticcytokineextractinthetreatmentofdryeyedisease AT luchsji safetyandefficacyofamnioticcytokineextractinthetreatmentofdryeyedisease AT solomonjd safetyandefficacyofamnioticcytokineextractinthetreatmentofdryeyedisease AT whitede safetyandefficacyofamnioticcytokineextractinthetreatmentofdryeyedisease AT guptapk safetyandefficacyofamnioticcytokineextractinthetreatmentofdryeyedisease
_version_	1718402912296632320

Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease

Ejemplares similares